EP1575985A4 - INHIBITION DE L'EXPRESSION DE Ii DANS DES CELLULES MAMMALIENNES - Google Patents

INHIBITION DE L'EXPRESSION DE Ii DANS DES CELLULES MAMMALIENNES

Info

Publication number
EP1575985A4
EP1575985A4 EP03721783A EP03721783A EP1575985A4 EP 1575985 A4 EP1575985 A4 EP 1575985A4 EP 03721783 A EP03721783 A EP 03721783A EP 03721783 A EP03721783 A EP 03721783A EP 1575985 A4 EP1575985 A4 EP 1575985A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
expression
mammalian cells
mammalian
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03721783A
Other languages
German (de)
English (en)
Other versions
EP1575985A2 (fr
Inventor
Minzhen Xu
Robert Humphreys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antigen Express Inc
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Publication of EP1575985A2 publication Critical patent/EP1575985A2/fr
Publication of EP1575985A4 publication Critical patent/EP1575985A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
EP03721783A 2002-04-22 2003-04-18 INHIBITION DE L'EXPRESSION DE Ii DANS DES CELLULES MAMMALIENNES Withdrawn EP1575985A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US127347 1987-12-01
US10/127,347 US20030198626A1 (en) 2002-04-22 2002-04-22 Inhibition of Ii expression in mammalian cells
PCT/US2003/012159 WO2003089453A2 (fr) 2002-04-22 2003-04-18 Inhibition de l'expression de ii dans des cellules mammaliennes

Publications (2)

Publication Number Publication Date
EP1575985A2 EP1575985A2 (fr) 2005-09-21
EP1575985A4 true EP1575985A4 (fr) 2009-05-27

Family

ID=29215245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03721783A Withdrawn EP1575985A4 (fr) 2002-04-22 2003-04-18 INHIBITION DE L'EXPRESSION DE Ii DANS DES CELLULES MAMMALIENNES

Country Status (6)

Country Link
US (1) US20030198626A1 (fr)
EP (1) EP1575985A4 (fr)
JP (1) JP2006506949A (fr)
AU (1) AU2003225076A1 (fr)
CA (1) CA2482993A1 (fr)
WO (1) WO2003089453A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278709A1 (en) * 2002-08-14 2004-03-03 Duke University Method of enhancing cd4+ t cell responses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034467A1 (fr) * 1998-12-04 2000-06-15 Antigen Express, Inc. Vaccin de cellules cancereuses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE163047T1 (de) * 1990-08-15 1998-02-15 Therion Biolog Corp Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
EP0671926B1 (fr) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Peptides immunomodulateurs
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US5827526A (en) * 1995-07-11 1998-10-27 Abbott Laboratories Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans
US5726020A (en) * 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368855B1 (en) * 1996-06-11 2002-04-09 Antigen Express, Inc. MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
WO2000034467A1 (fr) * 1998-12-04 2000-06-15 Antigen Express, Inc. Vaccin de cellules cancereuses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERTOLINO P ET AL: "CORRELATION BETWEEN INVARIANT CHAIN EXPRESSION LEVEL AND CAPABILITY TO PRESENT ANTIGEN TO MHC CLASS II-RESTRICTED T CELLS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 3, no. 5, 1 January 1991 (1991-01-01), pages 435 - 443, XP009048348, ISSN: 0953-8178 *
CLEMENTS VIRGINIA K ET AL: "Invariant chain alters the malignant phenotype of MHC class II-positive tumor cells", JOURNAL OF IMMUNOLOGY, vol. 149, no. 7, 1992, pages 2391 - 2396, XP002523314, ISSN: 0022-1767 *
HATANO M ET AL: "SPECIFIC INHIBITION OF CLASS II MHC GENE EXPRESSION BY ANTI-SENSE RNA", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 1, no. 3, 1 January 1989 (1989-01-01), pages 260 - 266, XP000619591, ISSN: 0953-8178 *

Also Published As

Publication number Publication date
AU2003225076A1 (en) 2003-11-03
AU2003225076A8 (en) 2003-11-03
JP2006506949A (ja) 2006-03-02
CA2482993A1 (fr) 2003-10-30
US20030198626A1 (en) 2003-10-23
EP1575985A2 (fr) 2005-09-21
WO2003089453A3 (fr) 2006-02-23
WO2003089453A2 (fr) 2003-10-30

Similar Documents

Publication Publication Date Title
EP1488816A4 (fr) Systeme de culture cellulaire ferme
AU2003223386A8 (en) Low-power high-performance memory cell and related methods
GB9900396D0 (en) Arrangements of electrochemical cells
AU2003279262A8 (en) Coatings for the inhibition of undesirable oxidation in an electrochemical cell
AU2003260351A8 (en) Cell culture insert
AU2003216822A8 (en) Stem cell culture
EP1482974A4 (fr) Procedes d'electroporation pour introduire des agents bioactifs dans des cellules
EP1521328A4 (fr) Cellule solaire
EP1557461A4 (fr) Composition destinee a la culture de cellules souches pluripotentes et utilisation de cette derniere
EP1536007A4 (fr) Chromosome mammifere artificiel
GB9900398D0 (en) Arrangements of electrochemical cells
AU2003240281A8 (en) Cell targeting methods and compositions
PL372328A1 (en) Inhibitors of alpha l beta 2 integrin mediated cell adhesion
AU2003292720A8 (en) Dihydrothienoquinoline derivatives and cell adhesion inhibitors containing the same
WO2004081030A8 (fr) Peptides selectivement letaux pour les cellules malignes et transformees
AU2003241857A8 (en) Method of counting microorganisms or cells
EP1490089A4 (fr) Peptides selectivement letaux pour des cellules de mammiferes transformees et malignes
AU2003225076A8 (en) Inhibition of ii expression in mammalian cells
AU2003284985A8 (en) Production of vanillin in microbial cells
ZA200501352B (en) Cell culture surface
GB0206765D0 (en) Method of single cell cloning in eukaryotic cell culture
AU2003217743A8 (en) Magnetic immobilization of cells
IL145056A0 (en) Expression of human alpha-fetoprotein in mammalian cells
GB0200804D0 (en) Cloning methods and other methods of producing cells
AU2003238008A8 (en) Method of cell growth inhibition with agnoprotein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041122

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101AFI20060307BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090428

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090728